- $1.93bn
- $676.81m
- $548.51m
Unit of China's Haisco, Eli Lilly sign collaboration, licensing deals
HUTCHMED Highlights Data to be Presented at ASCO
NMPA approval for ELUNATE with TYVYT
Brief: Hutchmed (China) Announces NDA For Sovleplenib Accepted With Priority Review By NMPA
HUTCHMED Announces NDA Acceptance in China
2025 Annual Report and Notice of AGM
Data to be Presented at AACR Annual Meeting 2026
Hutchmed Initiates Phase Iii Trial Of Hmpl: 760
Vesting of awards under Long Term Incentive Plan
Vesting of awards under Long Term Incentive Plan
Brief: Hutchmed (China) Says Ipsen Initiates Market Withdrawal And Recall Of Tazverik In China
Brief: HUTCHMED Announces Update on Licensed Oncology Product TAZVERIK® in China
Update on Licensed Oncology Product in China
Directorate change
Publication of Form 20-F
Brief: HUTCHMED (China) Logs FY Net Income Attributable $456.9 Mln
2025 Full Year Results and Business Updates
HUTCHMED Initiates Global Trial of ATTC Candidate
HUTCHMED to Announce 2025 Final Results